220 related articles for article (PubMed ID: 23109809)
1. Review of meta-analyses evaluating surrogate endpoints for overall survival in oncology.
Sherrill B; Kaye JA; Sandin R; Cappelleri JC; Chen C
Onco Targets Ther; 2012; 5():287-96. PubMed ID: 23109809
[TBL] [Abstract][Full Text] [Related]
2. Meta-analyses evaluating surrogate endpoints for overall survival in cancer randomized trials: A critical review.
Savina M; Gourgou S; Italiano A; Dinart D; Rondeau V; Penel N; Mathoulin-Pelissier S; Bellera C
Crit Rev Oncol Hematol; 2018 Mar; 123():21-41. PubMed ID: 29482777
[TBL] [Abstract][Full Text] [Related]
3. Statistical considerations and endpoints for clinical lung cancer studies: Can progression free survival (PFS) substitute overall survival (OS) as a valid endpoint in clinical trials for advanced non-small-cell lung cancer?
Pilz LR; Manegold C; Schmid-Bindert G
Transl Lung Cancer Res; 2012 Mar; 1(1):26-35. PubMed ID: 25806152
[TBL] [Abstract][Full Text] [Related]
4. Meta-analysis for the evaluation of surrogate endpoints in cancer clinical trials.
Shi Q; Sargent DJ
Int J Clin Oncol; 2009 Apr; 14(2):102-11. PubMed ID: 19390940
[TBL] [Abstract][Full Text] [Related]
5. Evaluating the evidence behind the surrogate measures included in the FDA's table of surrogate endpoints as supporting approval of cancer drugs.
Gyawali B; Hey SP; Kesselheim AS
EClinicalMedicine; 2020 Apr; 21():100332. PubMed ID: 32382717
[TBL] [Abstract][Full Text] [Related]
6. Significance of emerging clinical oncology endpoints in support of overall survival.
Patil S; Agarwal V; Drupad HS
Indian J Cancer; 2022 Mar; 59(Supplement):S106-S118. PubMed ID: 35343195
[TBL] [Abstract][Full Text] [Related]
7. Surrogate endpoints for overall survival in digestive oncology trials: which candidates? A questionnaires survey among clinicians and methodologists.
Methy N; Bedenne L; Bonnetain F
BMC Cancer; 2010 Jun; 10():277. PubMed ID: 20537166
[TBL] [Abstract][Full Text] [Related]
8. Surrogacy of intermediate endpoints for overall survival in randomized controlled trials of first-line treatment for advanced soft tissue sarcoma in the pre- and post-pazopanib era: a meta-analytic evaluation.
Tanaka K; Kawano M; Iwasaki T; Itonaga I; Tsumura H
BMC Cancer; 2019 Jan; 19(1):56. PubMed ID: 30634944
[TBL] [Abstract][Full Text] [Related]
9. Progression-Free Survival Early Assessment Is a Robust Surrogate Endpoint of Overall Survival in Immunotherapy Trials of Hepatocellular Carcinoma.
Cabibbo G; Celsa C; Enea M; Battaglia S; Rizzo GEM; Busacca A; Matranga D; Attanasio M; Reig M; Craxì A; Cammà C
Cancers (Basel); 2020 Dec; 13(1):. PubMed ID: 33396833
[TBL] [Abstract][Full Text] [Related]
10. Do Surrogate Endpoints Better Correlate with Overall Survival in Studies That Did Not Allow for Crossover or Reported Balanced Postprogression Treatments? An Application in Advanced Non-Small Cell Lung Cancer.
Hashim M; Pfeiffer BM; Bartsch R; Postma M; Heeg B
Value Health; 2018 Jan; 21(1):9-17. PubMed ID: 29304946
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of potential surrogate endpoints for prediction of overall survival in patients with castration-resistant prostate cancer: trial-level meta-analysis.
Chen W; Li L; Ji S; Song X; Lu W; Zhou T
Eur J Clin Pharmacol; 2019 Nov; 75(11):1521-1532. PubMed ID: 31463577
[TBL] [Abstract][Full Text] [Related]
12. Endpoints in cancer clinical trials.
Fiteni F; Westeel V; Pivot X; Borg C; Vernerey D; Bonnetain F
J Visc Surg; 2014 Feb; 151(1):17-22. PubMed ID: 24440056
[TBL] [Abstract][Full Text] [Related]
13. Combining tumour response and progression free survival as surrogate endpoints for overall survival in advanced colorectal cancer.
Elia EG; Städler N; Ciani O; Taylor RS; Bujkiewicz S
Cancer Epidemiol; 2020 Feb; 64():101665. PubMed ID: 31911395
[TBL] [Abstract][Full Text] [Related]
14. Tumor response and progression-free survival as potential surrogate endpoints for overall survival in extensive stage small-cell lung cancer: findings on the basis of North Central Cancer Treatment Group trials.
Foster NR; Qi Y; Shi Q; Krook JE; Kugler JW; Jett JR; Molina JR; Schild SE; Adjei AA; Mandrekar SJ
Cancer; 2011 Mar; 117(6):1262-71. PubMed ID: 20960500
[TBL] [Abstract][Full Text] [Related]
15. Poor correlation between progression-free and overall survival in modern clinical trials: are composite endpoints the answer?
Amir E; Seruga B; Kwong R; Tannock IF; Ocaña A
Eur J Cancer; 2012 Feb; 48(3):385-8. PubMed ID: 22115991
[TBL] [Abstract][Full Text] [Related]
16. A systematic review of meta-analyses assessing the validity of tumour response endpoints as surrogates for progression-free or overall survival in cancer.
Cooper K; Tappenden P; Cantrell A; Ennis K
Br J Cancer; 2020 Nov; 123(11):1686-1696. PubMed ID: 32913287
[TBL] [Abstract][Full Text] [Related]
17. Surrogate end points for overall survival in breast cancer trials: A review.
Fiteni F; Bonnetain F
Breast; 2016 Oct; 29():44-8. PubMed ID: 27400447
[TBL] [Abstract][Full Text] [Related]
18. A systematic review of trial-level meta-analyses measuring the strength of association between surrogate end-points and overall survival in oncology.
Haslam A; Hey SP; Gill J; Prasad V
Eur J Cancer; 2019 Jan; 106():196-211. PubMed ID: 30528804
[TBL] [Abstract][Full Text] [Related]
19. Surrogate endpoints for overall survival in lung cancer trials: a review.
Fiteni F; Westeel V; Bonnetain F
Expert Rev Anticancer Ther; 2017 May; 17(5):447-454. PubMed ID: 28399678
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
